![Matthew P. Pando](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Matthew P. Pando
Chief Executive Officer at Recognify Life Sciences, Inc.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Kristen MacFarlane | F | 60 |
Recognify Life Sciences, Inc.
![]() Recognify Life Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Recognify Life Sciences, Inc. develops treatments for cognitive impairment associated with schizophrenia. The company is based in Brisbane, CA. The company was founded by Thomas C. Südhof, Matthew P. Pando, Kristen Angela MacFarlane, Gary Walker. Matthew P. Pando has been the CEO since incorporation. | - |
Gary Walker | M | - |
Recognify Life Sciences, Inc.
![]() Recognify Life Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Recognify Life Sciences, Inc. develops treatments for cognitive impairment associated with schizophrenia. The company is based in Brisbane, CA. The company was founded by Thomas C. Südhof, Matthew P. Pando, Kristen Angela MacFarlane, Gary Walker. Matthew P. Pando has been the CEO since incorporation. | - |
Florian Brand | M | 37 |
Recognify Life Sciences, Inc.
![]() Recognify Life Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Recognify Life Sciences, Inc. develops treatments for cognitive impairment associated with schizophrenia. The company is based in Brisbane, CA. The company was founded by Thomas C. Südhof, Matthew P. Pando, Kristen Angela MacFarlane, Gary Walker. Matthew P. Pando has been the CEO since incorporation. | - |
Ryan Barrett | M | 43 |
Recognify Life Sciences, Inc.
![]() Recognify Life Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Recognify Life Sciences, Inc. develops treatments for cognitive impairment associated with schizophrenia. The company is based in Brisbane, CA. The company was founded by Thomas C. Südhof, Matthew P. Pando, Kristen Angela MacFarlane, Gary Walker. Matthew P. Pando has been the CEO since incorporation. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Loïc Maurel | M | 69 |
Exonhit
![]() Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 4 years |
Philippe Rousseau | M | 53 |
Exonhit
![]() Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 6 years |
Laurent Condomine | M | 79 |
Exonhit
![]() Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | - |
Deborah A. Smeltzer | F | 70 |
Exonhit
![]() Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | - |
Christophe Jean | M | 67 |
Exonhit
![]() Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | - |
Patrick J. Langlois | M | 78 |
Exonhit
![]() Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | - |
Laurent Bracco | M | - |
Exonhit
![]() Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | - |
Hervé Duchesne de Lamotte | M | 68 |
Exonhit
![]() Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 3 years |
Corinne Hoff | F | - |
Exonhit
![]() Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | - |
Frédéric Joël Desdouits | M | 57 |
Exonhit
![]() Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 3 years |
Michel Picot | M | 72 |
Exonhit
![]() Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | - |
Isabelle Barber | M | 55 |
Exonhit
![]() Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
France | 12 | 75.00% |
United States | 4 | 25.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Matthew P. Pando
- Personal Network